I-Mab commenced its commercial operations in November 2014, when its predecessor Third Venture Biopharma (Nanjing) Co. Ltd. was established.
I-Mab's fiscal year ends on December 31.
We have applied to list the ADSs on the Nasdaq Global Market under the symbol "IMAB".
Each ten (10) ADSs represent twenty-three (23) of our ordinary shares.
Annual reports are available via this website. All SEC documents are also accessible online through the SEC Filings page.
Skadden, Arps, Slate, Meagher & Flom LLP
Depositary Bank is Citi.
Jefferies LLC and China International Capital Corp. Hong Kong Securities Ltd. are acting as the book-running managers of I-Mab's offering and as the representatives of the underwriters. Also securing the deal are China Renaissance Securities (Hong Kong) Ltd. and Huatai Securities (USA) Inc.
The company intends to use the net proceeds from this offering for (i) research and development of the company’s existing and future drug candidates; (ii) potential investments in the establishment of I-Mab’s own manufacturing capacities and building research facilities in the United States, and (iii) general corporate purposes.